A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies

PHASE1TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Lymphoid Malignancies
Interventions
DRUG

HGS1029

HGS1029 will be given as a 15-minute IV infusion (in the vein) once weekly for 3 consecutive weeks, followed by 1 week off.

Trial Locations (5)

55905

Mayo Clinic, Rochester

07601

Hackensack University Medical Center, Hackensack

OX3 7LJ

Oxford Cancer and Haematology Centre, Headington

SM2 5NG

The Institute of Cancer Research, Belmont, Sutton, Surrey

SO16 6YD

Cancer Research UK Centre, Southampton

Sponsors
All Listed Sponsors
lead

Human Genome Sciences Inc.

INDUSTRY